Objective-Bempedoic acid (ETC-1002, 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid) is a novel low-density lipoprotein cholesterol-lowering compound. In animals, bempedoic acid targets the liver where it inhibits cholesterol and fatty acid synthesis through inhibition of ATP-citrate lyase and through activation of AMP-activated protein kinase. In this study, we tested the hypothesis that bempedoic acid would prevent diet-induced metabolic dysregulation, inflammation, and atherosclerosis.
C ardiovascular disease continues to be a major cause of death in developed countries, despite advances that have been made in lipid management therapy. Large-scale clinical trials have consistently shown that lowering plasma low-density lipoprotein (LDL) cholesterol (C) concentrations reduces cardiovascular disease mortality. 1 Statins have proven efficacy in lowering LDL-C and preventing cardiovascular disease events. Despite this, many at-risk patients are either unable to achieve their target LDL-C levels or are intolerant to statins because of side effects. 2, 3 This leaves a large group of individuals with significant residual risk, indicating a great need for additional therapeutics including novel lipid-lowering medications.
ATP citrate lyase (ACLY), a cytoplasmic enzyme responsible for the generation of acetyl coenzyme A (acetyl-CoA) for the de novo synthesis of fatty acids (FAs) and cholesterol, has recently emerged as a promising therapeutic target for the reduction of plasma lipids. 4 The ACLY inhibitor bempedoic acid (ETC-1002, 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid, BemA) was identified from the evaluation of a series of long hydrocarbon chain diacids for lipid-regulating activity. 5 Results from clinical trials up to Phase IIb have consistently shown as much as a 30% reduction in LDL-C and up to 40% lowering of high-sensitivity C-reactive protein. 4, [6] [7] [8] [9] In hypercholesterolemic patients on stable statin therapy, BemA treatment at 180 mg/d yielded 24% incremental reductions in LDL-C, indicating a complementary mechanism of action to statins. 10 In rodents, BemA targets 2 distinct molecular pathways within liver: ACLY and AMP-activated protein kinase (AMPK). 11 ACLY inhibition by BemA in rat hepatocytes rapidly reduces the levels of citrate-derived acetyl-CoA, the final common substrate for both FA and cholesterol synthesis. 11 ACLY is directly inhibited by a CoA thioester of BemA, 11 a reaction catalyzed by a liver-specific very long chain acylCoA synthetase-1 (ACSVL1). 12 In rodents, BemA-CoA activates AMPK in a liver kinase β1-dependent manner, without change in adenylate charge. 11, 12 Activation of AMPK by BemA phosphorylates and inhibits acetyl-CoA carboxylase (ACC) and hydroxymethylglutaryl-CoA reductase, contributing to the inhibition of both FA and cholesterol synthesis. 11 ACC inhibition depletes the malonyl-CoA pool for FA synthesis and relieves inhibition of Cpt1α-mediated FA β-oxidation by malonyl-CoA.
In rats and hamsters, BemA treatment increased hepatic protein expression of peroxisome proliferator-activated receptor γ coactivator 1-α and elevated plasma levels of β-hydroxybutyrate, suggesting increased FA β-oxidation.
11
In high-fat-fed hamsters or mice, short-term BemA treatment decreased plasma cholesterol and triglycerides, plasma glucose and insulin, and hepatic fat content. 11 In murine macrophages and adipose tissue explants, BemA downregulated proinflammatory signaling pathways. 6, 13 These results suggest BemA would be effective in the attenuation of metabolic dysregulation and inflammation, and prevent the development of atherosclerosis.
The objective of this study was to determine the impact of BemA on metabolic dysregulation, inflammation and atherosclerosis in a mouse model of the metabolic syndrome, namely the Ldlr −/− mouse fed a high-fat, cholesterol-containing diet. BemA treatment attenuated the elevation of plasma lipids, glucose, and insulin, and improved glucose tolerance. Reduced hepatic lipids were accompanied by suppressed inflammation. Lower aortic cholesteryl ester content and diminished aortic inflammation were associated with marked attenuation in atherosclerosis development.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
Bempedoic Acid Attenuates Weight Gain and Adipose Tissue Accumulation in HighFat, High-Cholesterol-Fed Ldlr −/− Mice Eight-week-old male Ldlr −/− mice were fed chow or a high-fat, high-cholesterol-containing diet (HFHC; 42% kcal fat, 0.2% cholesterol) supplemented with daily doses of 0, 3, 10, or 30 mg of BemA per kg body weight (mg/kg), for 12 weeks. The HFHC diet increased weight gain compared with chow-fed mice, which was partially prevented by treatment with 30 mg/ kg per day of BemA ( Figure 1A) . By 12 weeks, body weight was significantly less (−5%) than mice fed HFHC alone. At euthanization, the 4.5-fold increase in epididymal fat pad weight induced by the HFHC diet was significantly attenuated (−29%) by BemA at 30 mg/kg per day ( Figure 1B ). Microcomputed tomographic imaging revealed that total body fat significantly increased 3.1-fold in HFHC-fed mice compared with chow. BemA at 30 mg/kg per day decreased total adipose tissue content (−18%; Figure 1C ; Figure IA in the online-only Data Supplement). There was no difference in caloric intake among mice receiving the HFHC diet, with or without BemA ( Figure IB in the online-only Data Supplement). The 2 lower doses of BemA had no significant effect on body weight or adipose tissue mass.
Bempedoic Acid Decreases DietInduced Dyslipidemia
The HFHC diet induced significant hypertriglyceridemia and hypercholesterolemia by 4 weeks, which persisted throughout the study. By week 12, plasma cholesterol was significantly lower in BemA-treated mice at both 10 (−29%) and 30 mg/ kg per day (−41%; Figure 1D ). At week 12, plasma triglycerides were significantly lower in mice treated with 3 (−33%), 10 (−37%), and 30 mg/kg per day (−52%; Figure 1E ). The reduced plasma cholesterol in BemA-treated mice (30 mg/kg per day) was because of significant reductions in very lowdensity lipoprotein cholesterol (VLDL-C; −58%) and LDL-C (−26%; Figure 1F ). Plasma triglyceride reduction was confined to VLDL with a decrease of 49% at the 30 mg/kg per day dose ( Figure 1G ).
Bempedoic Acid Improves Glucose Metabolism and Insulin Sensitivity
The moderately elevated levels of blood glucose induced by the HFHC diet were significantly decreased by BemA at 30 mg/kg per day (−14%; Figure 1H ). The hyperinsulinemia in HFHC-fed mice was markedly attenuated with BemA at 10 (−23%) and 30 mg/kg per day (−50%; Figure 1I ). Glucose and insulin tolerance tests revealed a significant dosedependent improvement in glucose tolerance at 10 and 30 mg/kg per day, whereas insulin tolerance was unaffected by HFHC or BemA ( Figure IC and ID in the online-only Data Supplement). In liver, the HFHC diet induced significant increases in total cholesterol (TC, 4.3-fold), free cholesterol (FC; 1.5-fold) and cholesteryl ester (CE, 16-fold; Figure 2A ). Liver TC, FC, and CE were significantly lower with BemA at 10 (−54%, −23%, and −65%) and 30 mg/kg per day (−60%, −33%, and −70%). The HFHC diet-induced increase in liver triglyceride content (2.2-fold) was significantly lower with BemA treatment at 10 (−40%) and 30 mg/kg per day (−52%; Figure 2B ). This is consistent with histological analyses of liver sections, which revealed that treatment substantially decreased neutral lipid staining ( Figure To understand the molecular mechanisms underlying the metabolic improvements from BemA treatment, select hepatic gene and protein expressions were examined. Activation of AMPK was assessed by immunoblot for phosphorylated (p) AMPK and its target ACC ( Figure 2C and 2D ). Both pAMPK/tAMPK and pACC/tACC were suppressed in HFHC-fed mice compared with chow. Treatment at 30 mg/ kg per day significantly increased pAMPK/tAMPK (1.6-fold) and pACC/tACC (1.3-fold) relative to HFHC alone. Compared to HFHC-fed mice, total AMPK was decreased and total ACC was increased with treatment at 30 mg/kg per day ( Figure 2C ). At 30 mg/kg per day, BemA had no effect on Ppara mRNA, whereas Cpt1a and Acox1 expression were significantly increased (1.3-and 3-fold, respectively) consistent with the induction of hepatic FA oxidation in both mitochondria and peroxisomes. The elevated hepatic expression of Srebf1c (5-fold) in HFHC-fed mice was significantly lower in BemA-treated mice (−50%; Figure 2E ), which is most likely a response to the treatment-induced decrease in plasma insulin concentrations. Compared to the HFHC diet alone, hepatic expression of other lipogenic genes was generally increased with treatment at 30 mg/kg per day: Fasn (2-fold), Acaca (1.3-fold, trend), Acacb (1.4-fold), Srebf2 (1.2-fold, trend), Pcsk9 (1.7-fold, trend), and Hmgcr; (1.3-fold; Figure 2E ). This is consistent with a compensatory feedback response resulting from the inhibition of ACLY and reduced intracellular lipids. Compared to HFHC diet alone, Acly, Abca1, and Abcg1 expressions were unaffected by BemA treatment ( Figure 2F ). BemA did not affect Cyp7a1 or Cyp8b1 genes that regulate bile acid synthesis, whereas BemA increased the expression of genes coding for the halftransporters that promote hepatic cholesterol efflux into bile; Abcg5 (1.2-fold, trend) and Abcg8 (1.4-fold; Figure 2F ).
BemA at 30 mg/kg per day significantly increased hepatic FA β-oxidation (1.5-fold), compared with the HFHC diet alone ( Figure 3A) . The increase in hepatic FA-synthesis induced by the HFHC diet (2.8-fold) was significantly reduced by 30% with the treatment ( Figure 3B ). Muscle FA-synthesis increased significantly with the HFHC diet (3.5-fold) and was not affected further by BemA ( Figure III in the online-only Data Supplement). Hepatic synthesis of triglyceride and CE was significantly decreased by BemA at both 10 mg/kg per day (−42% and −48%) and 30 mg/kg per day (−52% and −65%), respectively ( Figure 3C and 3D ). Hepatic cholesterol synthesis was suppressed significantly by the HFHC diet (−85%), and was not further affected by BemA at 30 mg/kg per day ( Figure 3E ).
To further investigate the BemA-induced increase in hepatic FA-oxidation, whole body energy balance was assessed. Total energy expenditure was modestly, but significantly, higher (8%) in BemA-treated mice (30 mg/kg per −/− mice were fed chow, or a high-fat, high-cholesterol (HFHC) diet supplemented with BemA (0, 3, 10, or 30 mg/kg per day) for 12 weeks. A, Hepatic total cholesterol, free cholesterol, and cholesteryl ester (CE) content (n=14/group). B, Hepatic triglyceride (TG; n=14/group). C, Representative immunoblots (2 mice/group, all from the same blot) of phosphorylated (p) and total (t) AMPK and ACC in freeze-clamped liver lysates with quantitation (D; n=7-8/group). Ratios are normalized to chow-fed mice from the same immunoblot. E and F, mRNA expression of genes involved in hepatic lipid metabolism, expressed relative to Gapdh and normalized to values in chow-fed mice (n=10-12/group). Data are presented as mean±SEM. Different letters indicate significant differences (P<0.05).
day) compared with HFHC-fed mice ( Figure IVA and IVB in the online-only Data Supplement). The respiratory exchange ratio, which reflects the relative utilization of carbohydrate (respiratory exchange ratio ≈1.0) versus fat (respiratory exchange ratio ≈0.7), was similar between groups, indicating that increased energy expenditure in treated mice was associated with an increase in both carbohydrate and fat utilization ( Figure IVC in the online-only Data Supplement).
Bempedoic Acid Prevents Hepatic Inflammation
HFHC-induced hepatic inflammation and the effect of BemA were assessed by immunoblotting for mitogen-activated protein kinase and nuclear factor-κB signaling, 2 major inflammatory pathways linked to hepatic steatosis. 14, 15 Hepatic p38 and extracellular signal-regulated kinase 1/2 phosphorylation revealed little or no effect of the HFHC diet, whereas BemA treatment at 30 mg/kg per day significantly decreased signaling through these kinases (−40% and −52%, respectively; Figure  4A and 4B). Inflammatory gene expression is often mediated through nuclear factor-κB activation, which is regulated by the inhibitor of nuclear factor-κBα and its kinase, inhibitor of nuclear factor-κBα-kinase. However, hepatic inhibitor of nuclear factor-κBα-kinase and Iκ-Bα phosphorylation were unaffected either by the HFHC diet or by BemA ( Figure 4B ).
Hepatic inflammation was further assessed by measuring the expression of genes known to be markers of a macrophage M1 (inflammatory) or M2 (anti-inflammatory) phenotype. In general, the significantly elevated M1 inflammatory gene expression in HFHC-fed mice trended lower with 30 mg/kg per day BemA treatment and was significantly lower for the genes Ccl3 and Nos2 ( Figure 4C) . Expression of the M2 gene Arg1 was increased with treatment. The significantly elevated ratio of Nos2/Arg1 in HFHC-fed mice was significantly decreased by BemA, indicating the predominance of macrophages with an M2 phenotype ( Figure 4C ).
Chronic systemic inflammation was assessed by measuring the plasma levels of serum amyloid A (SAA). In response to inflammatory stimuli in obese mice, SAA expression increases in liver and adipose tissue, although only liverderived SAA contributes to circulating SAA levels. 16 The HFHC-fed mice showed a 1.3-fold increase in plasma concentrations of SAA at 12 weeks compared with baseline, and this was prevented (−45%) in the 30 mg/kg per day BemAtreated mice ( Figure 4D ).
Bempedoic Acid Prevents Aortic Lipid Accumulation, Inflammation, and Atherosclerotic Lesion Development
The aortic sinus was sectioned for histological examination of atherosclerotic lesion size and morphology. Analysis of Oil Red-O-stained sections revealed small lesions in chow-fed mice and much larger lesions (16-fold) in HFHC-fed mice. BemA treatment at 30 mg/kg per day robustly attenuated lesion size by 44% ( Figure 5A ). Compared to the HFHC-diet alone, treated mice had significantly fewer lesion macrophages (−46%) as assessed by CD68 staining, but relative to total lesion area, the percent of macrophages was unchanged ( Figure 5B ). The percent of lesion area occupied by smooth muscle α-actin trended lower (−8%; Figure 5C ) and that occupied by collagen as assessed by picrosirius red trended lower (−11%) with treatment, when compared with the HFHC-diet alone ( Figure 5D ). Levels of lesion apoptosis, which were determined by the number of cleaved caspase-3-positive nuclei as a percent of total nuclei, were significantly lower with treatment (0.6% versus 1.1%; Figure 5E ). In whole aortae, the HFHC-diet increased TC (1.7-fold), FC (1.4-fold), CE (4.4-fold), and triglyceride (2.4-fold) ( Figure 6A ). BemA significantly decreased TC (−30%), FC (−22%), and CE (−50%) at both 10 and 30 mg/kg per day doses. Aortic triglyceride was significantly decreased by 51% at 30 mg/kg per day. Collectively, these analyses indicate that BemA prevents lesion progression, resulting in smaller, lipid-depleted, less complex lesions.
Compared to chow-fed mice, the HFHC diet significantly increased aortic mRNA expression of macrophage M1 genes, Tnf, Il1b, Il6, Ccl2, and Nos2, all of which were significantly decreased by BemA at 30 mg/kg per day ( Figure 6B ). The HFHC diet had little effect on the expression of the M2 macrophage genes Arg1, Il10, and Cd163 and were not further affected by treatment. The M2 gene Chil3 was increased with the HFHC diet and decreased (trend) with treatment. The HFHC diet increased the ratio of Nos2/Arg1 (2.4-fold), whereas BemA completely reversed this expression pattern (−32%). This suggests that BemA treatment decreased aortic proinflammatory macrophages and increased the proportion of macrophages with M2 polarization.
Cell signaling cascades known to regulate the macrophage inflammatory response were assessed in full-length aortae ( Figure 6C and 6D) . Immunoblotting for extracellular signal-regulated kinase 1/2 phosphorylation revealed little effect of the HFHC diet and was not affected further by BemA at 30 mg/kg per day. Phosphorylation of p38 (p-p38/t-p38) and c-Jun N-terminal kinase 1 (JNK1 [pJNK1/tJNK1]) were significantly elevated by the HFHC diet, whereas BemA at 30 mg/kg per day significantly decreased signaling through these kinases (−30% and −45%, respectively). pJNK2/tJNK2 was unaffected by HFHC or BemA. A signal for pIκBα in the aorta was not detected, although tIκBα was increased by BemA ( Figure 6C and 6D) . Collectively, these data suggest that BemA diminishes aortic inflammation, in part, by attenuating diet-induced activation of inflammatory signaling cascades.
Discussion
Therapeutic strategies to alleviate atherosclerosis associated with the metabolic syndrome remain sparse. The results of this study demonstrate that ACLY inhibition together with AMPK activation by BemA attenuate the progression of several key metabolic disturbances that underlie the development of atherosclerosis. When Ldlr −/− mice were fed the HFHC diet, they exhibited obesity, dyslipidemia, hepatic steatosis, hepatic and aortic inflammation, and increased atherosclerosis. Addition of BemA at 3 mg/kg per day appeared to exhibit little effect and for most parameters; results were similar to the HFHC diet alone. However, the addition of BemA to the HFHC diet at 30 mg/kg per day effectively prevented or strongly attenuated hyperlipidemia, hepatic steatosis, adiposity, glucose intolerance and the rate of lesion development. The 10 mg/kg per day dose often showed similar potency to 30 mg/kg per day. BemA at 30 mg/kg per day also alleviated diet-induced inflammatory responses in liver, plasma and the aorta, thereby contributing to the attenuation of atherogenesis. Furthermore, BemA was associated with beneficial changes in lesion composition, including less lipid, fewer smooth muscle cells, more M2 cells and less apoptotic cells, all of which are characteristic of less mature lesions with a more stable phenotype.
The current experiments, together with previous studies, indicate that BemA primarily targets the liver. 11 This is based on the observations that ACSVL1-the enzyme that converts bempedoic acid to its active CoA derivative-is liver specific and BemA activates AMPK only through the β1-isoform, which is rodent liver specific. 12 In this study, BemA had a marked effect on hepatic lipid concentrations. In mice treated at 30 mg/kg per day, liver triglyceride was normalized and CE markedly decreased. This was attributed to increased FA β-oxidation and decreased de novo FA-and triglyceride-synthesis. Enhanced β-oxidation is consistent with the increase in hepatic expression of both Cpt1a and Acox1, which encode key enzymes in mitochondrial and peroxisomal FA metabolism, respectively. Malonyl-CoA normally inhibits Cpt1α. Thus, the expected decrease in malonyl-CoA in response to both ACLY inhibition and AMPK activation would relieve this inhibition. Reduced FA-synthesis was also an expected consequence of depleted hepatic malonyl-CoA. Increased hepatic expression of lipogenesis genes Fasn and Acacb may represent a compensatory response to the depletion of malonyl-CoA. The increase in Acacb mRNA and protein is likely secondary to the upregulation of ACC by citrate. Accumulation of hepatic citrate has been reported in rats in response to single-dose BemA treatment. 11 Despite this, the upregulation of gene expression must have been insufficient to overcome the greater inhibition of ACLY and the phosphorylation of ACC with BemA treatment because net FA-synthesis was markedly decreased. Collectively, these data are consistent with hepatic ACLY inhibition and AMPK activation by BemA. In an article published following the completion of this study, it was reported that in Apoe −/− mice fed a high-fat diet, BemA treatment improved parameters of lipid metabolism, including hepatic steatosis and plasma LDL-C independently of hepatic AMPK, implying that inhibition of ACLY was the primary mechanism for lipid regulation. 12 The modest increase in liver weight in BemA-treated mice was most likely because of peroxisome proliferation, as evidenced by the increase in the expression of the peroxisomespecific gene, Acox1. The increase in hepatic Ppara mRNA expression, typically observed with peroxisome proliferation in mice, 17 was not evident, suggesting that peroxisome proliferation was modest. Acox1 is the first enzyme of peroxisome FA β-oxidation, the pathway, responsible for the conversion of very long chain FAs to medium chain FAs, which are subsequently shuttled into mitochondria for complete β-oxidation.
Therefore, it is possible that peroxisome β-oxidation contributes to the BemA-induced increase in overall hepatic FA-oxidation.
Hepatic expression of Srebf1c is markedly increased in this mouse model, consistent with the hyperinsulinemia, as insulin is a potent transcriptional activator of Srebf1c. 18 BemA decreased plasma insulin and hepatic Srebf1c expression to a similar extent. Although this is consistent with the decreased FA synthesis, it does not fit with the upregulation of one of its target genes, Fasn. It is possible that the compensatory increase in Fasn expression induced by ACLY inhibition partially attenuated the decrease in Srebf1c.
In the Ldlr −/− mouse, plasma clearance of apoB-containing lipoproteins is impaired, leading to increased levels of VLDL and LDL. The HFHC diet-induced hepatic steatosis contributes significantly to hepatic overproduction of VLDL, increased cholesterol in both plasma VLDL and LDL fractions, and increased lesion formation. 18, 19 BemA attenuates atherosclerosis development in the aortic sinus, which was associated with a substantial reduction in plasma VLDL-C and LDL-C. Although not measured in this study, this was most likely because of the attenuation of hepatic VLDL overproduction consequent to the marked BemA-induced diminution of hepatic triglyceride and cholesterol content. The decreased size of aortic sinus lesions and marked reductions of aortic CE, TC, and triglyceride in treated mice are consistent with a study in which VLDL-C concentrations were a stronger predictor of aortic sinus atherosclerosis than that of LDL-C in Ldlr −/− mice fed a high-fat diet. 20 Thus, the marked reduction of VLDL-C along with the reduction in LDL-C contributes to the robust attenuation of lesion progression in BemA-treated mice.
BemA decreased hepatic cholesterol resulting in lower cholesterol concentrations in plasma and aortae. The mechanism(s) underlying this decrease are not entirely clear. Cholesterol absorption seems to be unaffected. Although BemA markedly suppressed hepatic cholesterol esterification, diminished hepatic cholesterol content is unlikely because of decreased cholesterol synthesis, as the suppressed rate of cholesterol synthesis in HFHC-fed mice was not further affected by BemA treatment. BemA may increase hepatic bile acid synthesis and enhance fecal acidic sterol excretion, although no increase in hepatic Cyp7a1 or Cyp8b1 expression was observed. Furthermore, BemA may increase fecal neutral sterol excretion via the bile or trans intestinal cholesterol efflux, as recently reported in statin-treated mice. 21 The latter is supported by increased hepatic expression of Abcg5 and Abcg8 and may explain the lower hepatic cholesterol and the increased hepatic expression of Hmgcr and the trends to increased Srebf2, Pcsk9, and cholesterol synthesis in BemAtreated mice. Future studies will be required to test these possibilities.
The HFHC diet-induced inflammatory response in liver and aortae is consistent with previous reports. 15, [22] [23] [24] In this study, we did not distinguish which cell type, Kupffer cells, or infiltrating macrophages, contributed to hepatic inflammation. The Adgre1 (F4/80) expression data suggested that the number of hepatic immune cells was not increased by the HFHC diet and the cytokine expression pattern indicated that they were predominantly an M1, proinflammatory phenotype. Although BemA treatment did not further affect Adgre1 expression in liver, suggesting no decrease in inflammatory cells, signaling through the mitogen-activated protein kinase erk pathway was attenuated, resulting in significantly reduced inflammatory responses in both liver and aortae. Furthermore, the gene expression pattern indicated a shift to a more anti-inflammatory, M2 phenotype. These findings extend a previous report that BemA decreased inflammatory cytokine expression in cultured macrophages and attenuated interleukin-6 release by inflamed adipose tissue ex vivo. 13 Mechanisms by which the added dietary cholesterol promote hepatic and aortic inflammation include increased cellular FC concentrations leading to mitochondrial dysfunction, stimulation of mitogen-activated protein kinase-and nuclear factor-κB-signaling, and activation of NLRP3 inflammasomes. 25, 26 The ability of BemA to diminish hepatic and aortic cholesterol may alleviate the FC-induced inflammatory stimulus in both tissues. Dietary saturated fat also promotes tissue inflammation. Incubation of macrophages with saturated FAs or VLDL containing saturated FAs enhances inflammatory cytokine secretion. 27, 28 Furthermore, diets rich in saturated fat induce macrophage infiltration into adipose tissue, liver, and aortae. 15, 23, 24, 29 Increased hepatic FA-oxidation in high-fat-fed transgenic mice overexpressing hepatic Cpt1a attenuated the expression of Tnfa, Il6, Il1b, and Ccl3 in liver and adipose tissue. 30 Moreover, in cultured macrophages exposed to excess palmitate, activation of AMPK increased FA-oxidation and suppressed inflammation. 31 Collectively, these results suggest that BemA's anti-inflammatory properties in the aortae are secondary to decreased exposure to lipoprotein-derived lipids, and in liver are because of its ability to stimulate FA-oxidation and inhibit FA-synthesis. However, a direct effect of BemA on inflammatory signaling pathways in these tissues cannot be ruled out.
BemA treatment robustly attenuated lesion size in the aortic sinus by 44%. A report published after completion of this study revealed that in Apoe −/− mice, BemA treatment (same dose, time, and diet as in this study) resulted in a small reduction in the size of aortic sinus lesions (−21%). 12 This was likely reflective of the modest reduction in total plasma cholesterol (−18%), and no effect on the high concentrations of chylomicron-and VLDL-remnant cholesterol, which are the primary atherogenic lipoproteins in this model. Lesion morphology was not reported. In this study, the aortic sinus lesions of HFHC-fed mice were characterized by infiltration of both neutral lipid-rich macrophages and smooth muscle cells. Lesions also displayed collagen deposition consistent with a fibrillar plaque phenotype. In contrast, BemA treatment significantly decreased lesion size and lesions were less advanced as evidenced by a similar proportion of macrophages that were predominantly a less-inflammatory M2 phenotype, a trend to fewer smooth muscle cells and collagen, and a significant reduction in the number of apoptotic cells. These data demonstrate that BemA attenuates the development and progression of atherosclerosis in Ldlr −/− mice induced by an HFHC diet.
In conclusion, these in vivo studies demonstrate that BemA ameliorates the dyslipidemia, hyperinsulinemia, and obesity in HFHC diet-fed Ldlr −/− mice, resulting in marked attenuation of atherosclerosis. Although other mechanisms may have contributed, BemA mediates its anti-atherogenic and anti-inflammatory effects through potent lipid lowering. These observations also suggest that the ability of BemA to decrease plasma lipids and high-sensitivity C-reactive protein in humans may also translate into the suppression of atherosclerosis.
